Top Suppliers:I want be here
Related CAS#:
56211-40-6 1189375-06-1
99300-68-2 1329613-35-5
99300-67-1 113844-99-8
947327-54-0 58155-35-4
160972-33-8 72810-61-8
1270286-75-3 1378866-74-0
1468650-99-8 1379314-54-1
1283717-87-2 1273676-46-2
799766-40-8 1269949-47-4
1889610-20-1 1270128-65-8

56211-40-6

56211-40-6 structure
56211-40-6 structure
  • Name: Torsemide
  • Chemical Name: torasemide
  • CAS Number: 56211-40-6
  • Molecular Formula: C16H20N4O3S
  • Molecular Weight: 348.420
  • Catalog: API Circulatory system medication Antihypertensive drug
  • Create Date: 2018-04-20 08:00:00
  • Modify Date: 2024-01-02 19:55:06
  • Torsemide is a pyridine-sulfonyl urea type loop diuretic.Target: OthersTorasemide is a pyridine-sulfonylurea type loop diuretic mainly used in the management of edema associated with congestive heart failure. It is also used at low doses for the management of hypertension. Torsemide significantly reduced total HF readmissions (relative risk [RR]: 0.41, 95% CI: 0.28-0.61, p < 0.0001) and HF readmissions (RR: 0.53, 95% CI: 0.33-0.84, p = 0.008) as well as CV readmissions (RR: 0.77, 95% CI: 0.60-0.98, p = 0.03) in patients with "at least 1 readmission." Torsemide caused a 14% reduction in all-cause mortality (RR: 0.86 [0.53-1.39], p = 0.54). Torsemide significantly reduces HF and CV-related hospital readmissions in systolic HF. Furthermore, torsemide is associated with a trend in reducing all-cause mortality [1]. Torsemide has several characteristics that make it suitable for treatment of advanced heart failure including longer half-life, increased potency of diuretic action, and anti-aldosterone effects. This case report details the administration of torsemide in 3 dogs with advanced heart failure and apparent furosemide resistance [2].
Name torasemide
Synonyms N-[[(1-Methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide
Unat
LUPLAC
EINECS 200-659-6
Toradiur
N-(Isopropylcarbamoyl)-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide
Demadex
Torem
JDL-464
N-(Isopropylcarbamoyl)-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide
3-Pyridinesulfonamide, N-[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-
N-[(1-Methylethyl)carbamoyl]-4-[(3-methylphenyl)amino]pyridin-3-sulfonamid
MFCD00866166
N-{[(1-methylethyl)amino]carbonyl}-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide
GJ-1090
N-[(1-methylethyl)carbamoyl]-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide
AC-4464
1-Isopropyl-3-[(4-m-toluidino-3-pyridyl)sulfonyl]urea
3-Isopropylcarbamylsulfonamido-4-(3'-methylphenyl)aminopyridine
Luprac
Torsemide
4-[(3-methylphenyl)amino]-N-(propan-2-ylcarbamoyl)pyridine-3-sulfonamide
Torasemide
Description Torsemide is a pyridine-sulfonyl urea type loop diuretic.Target: OthersTorasemide is a pyridine-sulfonylurea type loop diuretic mainly used in the management of edema associated with congestive heart failure. It is also used at low doses for the management of hypertension. Torsemide significantly reduced total HF readmissions (relative risk [RR]: 0.41, 95% CI: 0.28-0.61, p < 0.0001) and HF readmissions (RR: 0.53, 95% CI: 0.33-0.84, p = 0.008) as well as CV readmissions (RR: 0.77, 95% CI: 0.60-0.98, p = 0.03) in patients with "at least 1 readmission." Torsemide caused a 14% reduction in all-cause mortality (RR: 0.86 [0.53-1.39], p = 0.54). Torsemide significantly reduces HF and CV-related hospital readmissions in systolic HF. Furthermore, torsemide is associated with a trend in reducing all-cause mortality [1]. Torsemide has several characteristics that make it suitable for treatment of advanced heart failure including longer half-life, increased potency of diuretic action, and anti-aldosterone effects. This case report details the administration of torsemide in 3 dogs with advanced heart failure and apparent furosemide resistance [2].
Related Catalog
References

[1]. DiNicolantonio, J.J., Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiol, 2012. 8(5): p. 707-28.

[2]. Oyama, M.A., et al., Use of the loop diuretic torsemide in three dogs with advanced heart failure. J Vet Cardiol, 2011. 13(4): p. 287-92.
Density 1.3±0.1 g/cm3
Melting Point 163-164ºC
Molecular Formula C16H20N4O3S
Molecular Weight 348.420
Exact Mass 348.125610
PSA 108.57000
LogP 3.53
Index of Refraction 1.595
Storage condition -20°C Freezer
Water Solubility Soluble

CHEMICAL IDENTIFICATION

RTECS NUMBER :
UT7938000
CHEMICAL NAME :
3-Pyridinesulfonamide, N-(((1-methylethyl)amino)carbonyl)-4-((3-methylphenyl )amino)-
CAS REGISTRY NUMBER :
56211-40-6
LAST UPDATED :
199612
DATA ITEMS CITED :
10
MOLECULAR FORMULA :
C16-H20-N4-O3-S
MOLECULAR WEIGHT :
348.46

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Kidney, Ureter, Bladder - urine volume increased
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 22(Suppl 5),S975,1994
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>500 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - respiratory depression Kidney, Ureter, Bladder - urine volume increased
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 22(Suppl 5),S975,1994
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
APFRAD Annales Pharmaceutiques Francaises. (SPPIF, B.P.22, F-41353 Vineuil, France) V.1- 1943- Volume(issue)/page/year: 36,369,1978
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>3 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
APFRAD Annales Pharmaceutiques Francaises. (SPPIF, B.P.22, F-41353 Vineuil, France) V.1- 1943- Volume(issue)/page/year: 36,369,1978
TYPE OF TEST :
LD - Lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
>2 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 22(Suppl 5),S983,1994 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1825 mg/kg/52W-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in bladder weight Endocrine - changes in adrenal weight Nutritional and Gross Metabolic - weight loss or decreased weight gain
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 22(Suppl 5),S1043,1994
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
72800 ug/kg/13W-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Kidney, Ureter, Bladder - other changes in urine composition Endocrine - changes in adrenal weight
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 22(Suppl 5),S1005,1994
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
146 mg/kg/52W-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Blood - other changes Nutritional and Gross Metabolic - changes in sodium
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 22(Suppl 5),S1071,1994 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
330 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 22(Suppl 5),S1113,1994
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
400 mg/kg
SEX/DURATION :
female 17-21 day(s) after conception lactating female 20 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - physical
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 22(Suppl 5),S1143,1994
Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H319
Precautionary Statements P305 + P351 + P338
Personal Protective Equipment dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes Xi: Irritant;
Risk Phrases R36
Safety Phrases 26-37/39
RIDADR NONH for all modes of transport
RTECS UT7938000
HS Code 2935009090
72811-73-5 structure

72811-73-5

1795-48-8 structure

1795-48-8

~99%

56211-40-6 structure

56211-40-6

Literature: COSMA S.P.A. Patent: US2004/138469 A1, 2004 ; Location in patent: Page 4 ;
17614-10-7 structure

17614-10-7

72811-73-5 structure

72811-73-5

~90%

56211-40-6 structure

56211-40-6

Literature: FINETECH LABORATORIES LTD. Patent: WO2003/97603 A1, 2003 ; Location in patent: Page/Page column 46-47 ;
51498-37-4 structure

51498-37-4

~%

56211-40-6 structure

56211-40-6

Literature: WO2004/9554 A1, ; Page 5-6 ;
33263-43-3 structure

33263-43-3

108-44-1 structure

108-44-1

1795-48-8 structure

1795-48-8

~%

56211-40-6 structure

56211-40-6

Literature: Arzneimittel-Forschung, , vol. 38, # 1 A p. 144 - 150
160822-47-9 structure

160822-47-9

1795-48-8 structure

1795-48-8

~88%

56211-40-6 structure

56211-40-6

Literature: Brantford Chemicals Inc. Patent: US2005/209460 A1, 2005 ; Location in patent: Page/Page column 3 ;
HS Code 2935009090
Summary 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0%

Chemsrc provides CAS#:56211-40-6 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 56211-40-6 | Chemsrc address: https://www.chemsrc.com/en/baike/324873.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved